Journal Scans
The Potential Benefit of 6 vs 3 Cycles of Chemotherapy in Subsets of Women With Early-Stage High-Risk Epithelial Ovarian Cancer: An Exploratory Analysis of a Gynecologic Oncology Group Study
Recurrence Benefit of 6 Cycles in Early Ovarian Cancer
JK Chan, C Tian, GF Fleming, BJ Monk, TJ Herzog, DS Kapp, J Bell
20100201
2010 Mar 1
Gynecol Oncol
The Potential Benefit of 6 vs 3 Cycles of Chemotherapy in Subsets of Women With Early-Stage High-Risk Epithelial Ovarian Cancer: An Exploratory Analysis of a Gynecologic Oncology Group Study
Gynecol Oncol. 2010 Mar 1;116(3):301-306, JK Chan, C Tian, GF Fleming, BJ Monk, TJ Herzog, DS Kapp, J Bell
TAKE-HOME MESSAGE
Abstract
Abstract
Objectives: A prior clinical trial on early-stage high risk ovarian cancer showed a lower recurrence rate in those treated with six vs. three cycles of chemotherapy. We proposed to identify subsets of patients who may benefit from more cycles of chemotherapy. Methods: Outcomes of patients who underwent six vs. three cycles of chemotherapy were analyzed based on clinico-pathologic factors. Kaplan–Meier estimates and Cox Regression Model were used for analyses.Results: Of 427 patients (median age:...
